Copyright Reports & Markets. All rights reserved.

Dermatomyositis - Pipeline Review, H2 2019

Buy now

Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Dermatomyositis - Overview

              Dermatomyositis - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Products under Development by Companies

                      Dermatomyositis - Therapeutics Assessment

                        Assessment by Target

                          Assessment by Mechanism of Action

                            Assessment by Route of Administration

                              Assessment by Molecule Type

                                Dermatomyositis - Companies Involved in Therapeutics Development

                                  Biocon Ltd

                                    Bristol-Myers Squibb Co

                                      Chugai Pharmaceutical Co Ltd

                                        Corbus Pharmaceuticals Inc

                                          CSL Ltd

                                            Eli Lilly and Co

                                              GNI Group Ltd

                                                Hope Pharmaceuticals Inc

                                                  Johnson & Johnson

                                                    Kezar Life Sciences Inc

                                                      Neovacs SA

                                                        NovelMed Therapeutics Inc

                                                          Octapharma AG

                                                            Pfizer Inc

                                                              ReveraGen BioPharma Inc

                                                                Viela Bio Inc

                                                                  Dermatomyositis - Drug Profiles

                                                                    abatacept - Drug Profile

                                                                      Product Description

                                                                        Mechanism Of Action

                                                                          R&D Progress

                                                                            baricitinib - Drug Profile

                                                                              Product Description

                                                                                Mechanism Of Action

                                                                                  R&D Progress

                                                                                    BVX-20 - Drug Profile

                                                                                      Product Description

                                                                                        Mechanism Of Action

                                                                                          R&D Progress

                                                                                            immune globulin (human) - Drug Profile

                                                                                              Product Description

                                                                                                Mechanism Of Action

                                                                                                  R&D Progress

                                                                                                    immune globulin (human) - Drug Profile

                                                                                                      Product Description

                                                                                                        Mechanism Of Action

                                                                                                          R&D Progress

                                                                                                            KZR-616 - Drug Profile

                                                                                                              Product Description

                                                                                                                Mechanism Of Action

                                                                                                                  R&D Progress

                                                                                                                    lenabasum - Drug Profile

                                                                                                                      Product Description

                                                                                                                        Mechanism Of Action

                                                                                                                          R&D Progress

                                                                                                                            Monoclonal Antibodies for Dermatomyositis - Drug Profile

                                                                                                                              Product Description

                                                                                                                                Mechanism Of Action

                                                                                                                                  R&D Progress

                                                                                                                                    PF-06823859 - Drug Profile

                                                                                                                                      Product Description

                                                                                                                                        Mechanism Of Action

                                                                                                                                          R&D Progress

                                                                                                                                            pirfenidone - Drug Profile

                                                                                                                                              Product Description

                                                                                                                                                Mechanism Of Action

                                                                                                                                                  R&D Progress

                                                                                                                                                    sodium thiosulfate - Drug Profile

                                                                                                                                                      Product Description

                                                                                                                                                        Mechanism Of Action

                                                                                                                                                          R&D Progress

                                                                                                                                                            tocilizumab - Drug Profile

                                                                                                                                                              Product Description

                                                                                                                                                                Mechanism Of Action

                                                                                                                                                                  R&D Progress

                                                                                                                                                                    tofacitinib citrate - Drug Profile

                                                                                                                                                                      Product Description

                                                                                                                                                                        Mechanism Of Action

                                                                                                                                                                          R&D Progress

                                                                                                                                                                            tofacitinib citrate ER - Drug Profile

                                                                                                                                                                              Product Description

                                                                                                                                                                                Mechanism Of Action

                                                                                                                                                                                  R&D Progress

                                                                                                                                                                                    ustekinumab - Drug Profile

                                                                                                                                                                                      Product Description

                                                                                                                                                                                        Mechanism Of Action

                                                                                                                                                                                          R&D Progress

                                                                                                                                                                                            Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders - Drug Profile

                                                                                                                                                                                              Product Description

                                                                                                                                                                                                Mechanism Of Action

                                                                                                                                                                                                  R&D Progress

                                                                                                                                                                                                    vamorolone - Drug Profile

                                                                                                                                                                                                      Product Description

                                                                                                                                                                                                        Mechanism Of Action

                                                                                                                                                                                                          R&D Progress

                                                                                                                                                                                                            VIB-7734 - Drug Profile

                                                                                                                                                                                                              Product Description

                                                                                                                                                                                                                Mechanism Of Action

                                                                                                                                                                                                                  R&D Progress

                                                                                                                                                                                                                    Dermatomyositis - Dormant Projects

                                                                                                                                                                                                                      Dermatomyositis - Discontinued Products

                                                                                                                                                                                                                        Dermatomyositis - Product Development Milestones

                                                                                                                                                                                                                          Featured News & Press Releases

                                                                                                                                                                                                                            Jun 12, 2019: Lenabasum open-label extension data to be presented at EULAR 2019 continue to show a favorable safety profile and improvement in efficacy outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Studies

                                                                                                                                                                                                                              Apr 01, 2019: Neovacs announces an agreement with Biosyn to diversify its supply of Keyhole Limpet Hemocyanin

                                                                                                                                                                                                                                Dec 18, 2018: Corbus Pharmaceuticals announces Issuance of Composition of Matter Patent related to Lenabasum

                                                                                                                                                                                                                                  Dec 17, 2018: Corbus Pharmaceuticals initiates “DETERMINE” phase 3 study in Dermatomyositis

                                                                                                                                                                                                                                    Sep 20, 2018: Corbus Pharmaceuticals provides update on Lenabasum

                                                                                                                                                                                                                                      Jul 25, 2018: Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis

                                                                                                                                                                                                                                        Jul 20, 2018: Corbus Pharmaceuticals receives FDA Orphan Drug Designation for Lenabasum for the treatment of Dermatomyositis

                                                                                                                                                                                                                                          Jun 06, 2018: GNI Group Initiates Etuary Phase III Trial in China for CTD-ILD

                                                                                                                                                                                                                                            Apr 26, 2018: Corbus Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference

                                                                                                                                                                                                                                              Mar 02, 2018: Corbus Pharmaceuticals to Present at the Cowen & Co. 38th Annual Health Care Conference

                                                                                                                                                                                                                                                Feb 06, 2018: Corbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference

                                                                                                                                                                                                                                                  Nov 27, 2017: Corbus Pharmaceuticals Expands Intellectual Property Portfolio with Patent Issuance Covering the Use of Anabasum for the Treatment of Rare Fibrotic Diseases

                                                                                                                                                                                                                                                    Oct 31, 2017: Corbus Pharmaceuticals Announces New Patent Issuance Covering the Use of Anabasum for the Treatment of Inflammatory Diseases

                                                                                                                                                                                                                                                      Oct 19, 2017: Corbus Pharmaceuticals Reports Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis

                                                                                                                                                                                                                                                        Jul 19, 2017: Neovacs Announces FDA Acceptance of a New IND to Expand in U.S. IFN-alpha Kinoid Clinical Development Program in Dermatomyositis

                                                                                                                                                                                                                                                          Appendix

                                                                                                                                                                                                                                                            Methodology

                                                                                                                                                                                                                                                              Coverage

                                                                                                                                                                                                                                                                Secondary Research

                                                                                                                                                                                                                                                                  Primary Research

                                                                                                                                                                                                                                                                    Expert Panel Validation

                                                                                                                                                                                                                                                                      Contact Us

                                                                                                                                                                                                                                                                        Disclaimer

                                                                                                                                                                                                                                                                        Dermatomyositis - Pipeline Review, H2 2019

                                                                                                                                                                                                                                                                        Summary

                                                                                                                                                                                                                                                                        Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis - Pipeline Review, H2 2019, provides an overview of the Dermatomyositis (Musculoskeletal Disorders) pipeline landscape.

                                                                                                                                                                                                                                                                        Dermatomyositis is a rare inflammatory disease which is characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.

                                                                                                                                                                                                                                                                        Report Highlights

                                                                                                                                                                                                                                                                        Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dermatomyositis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Dermatomyositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

                                                                                                                                                                                                                                                                        The Dermatomyositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 4, 3, 2, 1 and 1 respectively.

                                                                                                                                                                                                                                                                        Dermatomyositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

                                                                                                                                                                                                                                                                        Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

                                                                                                                                                                                                                                                                        Scope

                                                                                                                                                                                                                                                                        - The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomyositis (Musculoskeletal Disorders).
                                                                                                                                                                                                                                                                        - The pipeline guide reviews pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
                                                                                                                                                                                                                                                                        - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
                                                                                                                                                                                                                                                                        - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
                                                                                                                                                                                                                                                                        - The pipeline guide reviews key companies involved in Dermatomyositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
                                                                                                                                                                                                                                                                        - The pipeline guide evaluates Dermatomyositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
                                                                                                                                                                                                                                                                        - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
                                                                                                                                                                                                                                                                        - The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders)

                                                                                                                                                                                                                                                                        Reasons to buy

                                                                                                                                                                                                                                                                        - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
                                                                                                                                                                                                                                                                        - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
                                                                                                                                                                                                                                                                        - Find and recognize significant and varied types of therapeutics under development for Dermatomyositis (Musculoskeletal Disorders).
                                                                                                                                                                                                                                                                        - Classify potential new clients or partners in the target demographic.
                                                                                                                                                                                                                                                                        - Develop tactical initiatives by understanding the focus areas of leading companies.
                                                                                                                                                                                                                                                                        - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
                                                                                                                                                                                                                                                                        - Formulate corrective measures for pipeline projects by understanding Dermatomyositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
                                                                                                                                                                                                                                                                        - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
                                                                                                                                                                                                                                                                        - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

                                                                                                                                                                                                                                                                        Buy now